Middle East respiratory syndrome (MERS) Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageMiddle East respiratory syndrome (MERS) MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:28 May 2023Last updated:22 Jun 2023SummaryMiddle East respiratory syndrome (MERS) should be considered when . Vaccines are undergoing trials.Epidemic potential is considered low at present unless the virus mutates.DefinitionMiddle East respiratory syndrome (MERS) is an acute viral respiratory tract infection caused by the novel betacoronavirus MERS coronavirus (MERS-CoV). It was first identified in Saudi Arabia in 2012. Cases have been limited to the Arabian Peninsula and its surrounding countries
Middle East Respiratory Syndrome Coronavirus (MERS-CoV): testing Skip to main contentCookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites to help us deliver content from their services.Accept additional cookiesReject additional cookiesView cookies GOV.UKNavigation menuMenuSearch GOV.UKHomeHealth and social carePublic healthHealth protectionInfectious diseasesGuidanceMiddle East Respiratory Syndrome Coronavirus (MERS-CoV): testingExplains the process for both primary and confirmatory testing of human samples for MERS-CoV testing, when MERS is being considered as a diagnosis.From:UK Health Security
Middle East respiratory syndrome (MERS-CoV) risk assessment Middle East Respiratory Syndrome (MERS-CoV) risk assessment - GOV.UK Skip to main content Cookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites to help us account: sign in 1. Home 2. Health and social care 3. Public health 4. Health protection 5. Health surveillance and reporting programmes Guidance Middle East Respiratory Syndrome (MERS-CoV) risk assessment Guidance on reducing the risk of getting MERS-CoV for UK residents and travellers to the Middle East.From: UK Health Security Agency Published 2 May 2014 Last updated 1 July 2022 — See all
MERS-CoV: public health investigation and management of possible cases MERS-CoV: public health investigation and management of possible cases - GOV.UK Skip to main content Cookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set * Universal Credit account: sign in 1. Home 2. Health and social care 3. Public health Guidance MERS-CoV: public health investigation and management of possible cases Algorithm on public health investigation and management of possible cases of MERS-CoV (Middle East respiratory syndrome coronavirus). From: UK Health Security Agency Published 14 July 2014 Last updated 4 April 2022 — See all updates Get
MERS-CoV: advice for travellers returning from the Middle East MERS-CoV: advice for travellers returning from the Middle East - GOV.UK Skip to main content Cookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites account: sign in 1. Home 2. Health and social care 3. Public health Guidance MERS-CoV: advice for travellers returning from the Middle East Infographics with advice for people travelling to the UK from the Middle East.From: UK Health Security Agency Published 13 September 2016 Last updated 29 June 2022 — See all updates Get emails about this page DocumentsMERS-CoV Middle East respiratory syndrome
PC-mer: An Ultra-fast memory-efficient tool for metagenomics profiling and classification. Features extraction methods, such as k-mer-based methods, have recently made up a significant role in classifying and analyzing approaches for metagenomics data. But, they are challenged by various bottlenecks, such as performance limitations, high memory consumption, and computational overhead. To deal with these challenges, we developed an innovative features extraction and sequence profiling method for DNA/RNA sequences, called PC-mer, taking advantage of the physicochemical properties of nucleotides. PC-mer in comparison with the k-mer profiling methods provides a considerable memory usage reduction by a factor of 2k while improving the metagenomics classification performance, for both machine learning-based
Gene sequence analysis model construction based on k-mer statistics. With the rapid development of biotechnology, gene sequencing methods are gradually improved. The structure of gene sequences is also more complex. However, the traditional sequence alignment method is difficult to deal with the complex gene sequence alignment work. In order to improve the efficiency of gene sequence analysis, D2 series method of k-mer statistics is selected to build the model of gene sequence alignment analysis. According to the structure of the foreground sequence, the sequence to be aligned can be cut by different lengths and divided into multiple subsequences. Finally, according to the selected subsequences, the maximum dissimilarity in the alignment results is determined as the statistical result
Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial MERS-CoV is a respiratory pathogen with a case-fatality rate of 36%, and for which no vaccines are currently licensed. MVA-MERS-S is a candidate vaccine based on recombinant modified vaccinia virus Ankara (MVA). In this study, the safety, immunogenicity, and optimal dose schedule of MVA-MERS-S was assessed in individuals with previous exposure to SARS-CoV-2 infections and vaccines. We conducted a multicentre, double-blind, randomised controlled phase 1b clinical trial at two university medical centres in Germany and the Netherlands. Healthy volunteers aged 18-55 years were assigned by computer
MERS-CoV‒Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination. We developed an ELISPOT assay for evaluating Middle East respiratory syndrome coronavirus (MERS-CoV)‒specific T-cell responses in dromedary camels. After single modified vaccinia virus Ankara-MERS-S vaccination, seropositive camels showed increased levels of MERS-CoV‒specific T cells and antibodies, indicating
SAKE: Strobemer-assisted k-mer extraction. K-mer-based analysis plays an important role in many bioinformatics applications, such as de novo assembly, sequencing error correction, and genotyping. To take full advantage of such methods, the k-mer content of a read set must be captured as accurately as possible. Often the use of long k-mers is preferred because they can be uniquely associated with a specific genomic region. Unfortunately, it is not possible to reliably extract long k-mers in high error rate reads with standard exact k-mer counting methods. We propose SAKE, a method to extract long k-mers from high error rate reads by utilizing strobemers and consensus k-mer generation through partial order alignment. Our experiments show that on simulated data with up to 6% error rate, SAKE can
A randomized optimal k-mer indexing approach for efficient parallel genome sequence compression. Next Generation Sequencing (NGS) technology generates massive amounts of genome sequence that increases rapidly over time. As a result, there is a growing need for efficient compression algorithms to facilitate the processing, storage, transmission, and analysis of large-scale genome sequences. Over the past 31 years, numerous state-of-the-art compression algorithms have been developed. The performance of any compression algorithm is measured by three main compression metrics: compression ratio, time, and memory usage. Existing k-mer hash indexing systems take more time, due to the decision-making process based on compression results. In this paper, we propose a two-phase reference genome
Biphasic MERS-CoV Incidence in Nomadic Dromedaries with Putative Transmission to Humans, Kenya, 2022-2023. Middle East respiratory syndrome coronavirus (MERS-CoV) is endemic in dromedaries in Africa, but camel-to-human transmission is limited. Sustained 12-month sampling of dromedaries in a Kenya abattoir hub showed biphasic MERS-CoV incidence; peak detections occurred in October 2022 and February 2023. Dromedary-exposed abattoir workers (7/48) had serologic signs of previous MERS-CoV exposure.
Brief Report: Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Subjects Vaccinated with Modified Vaccinia Virus Ankara Encoding MERS-Coronavirus Spike Protein. Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus (MPXV) and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome- associated coronavirus (MERS -CoV). Here, we report that cross-reactive MPXV nAbs were detectable in only a single subject after the first dose, 3 out of 10 after the 2nd dose, and in 10 out of 10 after the 3rd dose of MVA-MERS-S vaccine.
Extended Viral Shedding of MERS-CoV Clade B Virus in Llamas Compared with African Clade C Strain. Middle East respiratory syndrome coronavirus (MERS-CoV) clade B viruses are found in camelids and humans in the Middle East, but clade C viruses are not. We provide experimental evidence for extended shedding of MERS-CoV clade B viruses in llamas, which might explain why they outcompete clade C
Impact of proactive and reactive vaccination strategies for health-care workers against MERS-CoV: a mathematical modelling study. Several vaccine candidates are in development against MERS-CoV, which remains a major public health concern. In anticipation of available MERS-CoV vaccines, we examine strategies for their optimal deployment among health-care workers. Using data from the 2013-14 Saudi -level campaigns is greatly reduced; the impact of regional-level campaigns is variable, but that of national-level campaigns is preserved unless triggers have high thresholds. Substantial reduction of MERS-CoV morbidity and mortality is possible when vaccinating only health-care workers, underlining the need for countries at risk of outbreaks to stockpile vaccines when available. UK Medical Research
Symptomatic MERS-CoV infection reduces the risk of future COVID-19 disease; a retrospective cohort study. The general human immune responses similarity against different coronaviruses may reflect some degree of cross-immunity, whereby exposure to one coronavirus may confer partial immunity to another. The aim was to determine whether previous MERS-CoV infection was associated with a lower risk of subsequent COVID-19 disease and its related outcomes. We conducted a retrospective cohort study among all patients screened for MERS-CoV at a tertiary care hospital in Saudi Arabia between 2012 and early 2020. Both MERS-CoV positive and negative patients were followed up from early 2020 to September 2021 for developing COVID-19 infection confirmed by RT-PCR testing. A total of 397 participants followed
IL-13 induced inflammation increases DPP4 abundance but does not enhance MERS-CoV replication in airway epithelia. Chronic pulmonary conditions such as asthma and COPD increase the risk of morbidity and mortality during infection with the Middle East respiratory syndrome coronavirus (MERS-CoV). We hypothesized that individuals with such comorbidities are more susceptible to MERS-CoV infection due to increased expression of its receptor, dipeptidyl peptidase 4 (DPP4). We modeled chronic airway disease by treating primary human airway epithelia with the Th2 cytokine IL-13, examining how this impacted DPP4 protein levels along with MERS-CoV entry and replication. IL-13 exposure for 3 days led to increased DPP4 protein abundance, while a 21-day treatment increased DPP4 levels and caused
SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers. SLN124, an N-acetylgalactosamine conjugated 19-mer short interfering RNA, is being developed to treat iron-loading anemias (including beta-thalassemia and myelodysplastic syndromes) and myeloproliferative neoplasms (polycythemia vera). Through hepatic targeting
Protein expression/secretion boost by a novel unique 21-mer cis-regulatory motif (Exin21) via mRNA stabilization. Boosting protein production is invaluable in both industrial and academic applications. We discovered a novel expression-increasing 21-mer cis-regulatory motif (Exin21) that inserts between SARS-CoV-2 envelope (E) protein-encoding sequence and luciferase reporter gene. This unique